The Pharma Data

SEPTEMBER 7, 2021

Bristol Myers Squibb has a global exclusive license to develop, manufacture and commercialize the Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. Contributions to Research, Life-Sciences Industry.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

DECEMBER 20, 2020

This oncolytic virus has induced long-lasting antitumor immune responses and abscopal effects in several tumor models, and its activity is further enhanced through combination with an anti-PD-1 antibody treatment. BioInvent International AB (publ) Co. LUND, Sweden and STRASBOURG, France , Dec. About BioInvent.

Virus 40

Virus Trials Clinical Trials Clinical Development 40

The Pharma Data

DECEMBER 15, 2020

The condition affects the skin and internal organs and is driven by inflammation and fibrosis, which can lead to severe damage and failure of several multiple body organs. CUE-300 Series Immuno-STATs may offer autoimmune patients therapeutic benefits without compromising their immune systems.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. Internal Medicine. These results were presented in August at the Digital International Liver Congress 2020. approval in 2021.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

NOVEMBER 29, 2020

To access the conference call, please dial +1 877 870 9135 (from the US) or +44 2071 928338 (international) and refer to conference ID 4469307. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Codon

JULY 27, 2023

A company, Agragene , has now started greenhouse tests with this technology (it’s licensed from Synvect, a spin-out from Omar Akbari’s lab at the University of California, San Diego). a lower risk of immune responses. The male fertility gene is beta-tubulin, which helps sperm swim.) ” And a third paper (BOOM!)

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

A company, Agragene , has now started greenhouse tests with this technology (it’s licensed from Synvect, a spin-out from Omar Akbari’s lab at the University of California, San Diego). a lower risk of immune responses. The male fertility gene is beta-tubulin, which helps sperm swim.) ” And a third paper (BOOM!)

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Production 52

Production Marketing Research DNA 52

The Pharma Data

APRIL 27, 2021

up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. MRT5500 (SP0254), an mRNA vaccine candidate against SARS-CoV-2, entered Phase 1/2 to assess safety, immune response and reactogenicity. Collaborations.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

MAY 6, 2021

It is the decision of sovereign States to offer immunization to athletes and their delegations in accordance with their local guidance before travelling to Japan for the Tokyo Games. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Discovering the T cell response to replication proteins.

Vaccine 52

Vaccine Immune Response Virus International 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. J Intern Med 2012;272:121–32. 6 Kupczyk M, Wenzel S.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

JUNE 18, 2021

“Adult vaccinations play a pivotal role in helping protect our health and wellness, especially as we age and our immune systems begin to naturally weaken,” said Jane Barratt, Ph.D., Secretary General, International Federation on Ageing (IFA). “We The indication for preventing pneumonia caused by S. IMPORTANT SAFETY INFORMATION.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.(24,25) 2016;116:37-42.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

DECEMBER 21, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2019;12(5):539-549. Wenzel S. Eur Respir J.

Trials 40

Trials Production Clinical Trials Therapies 40

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. NanoFlu , its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. NanoFlu , its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

FEBRUARY 8, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. The CRL refers to certain deficiencies identified by the agency during a pre-license inspection of a third-party facility responsible for manufacturing. glucosidase deficiency).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. The CRL refers to certain deficiencies identified by the agency during a pre-license inspection of a third-party facility responsible for manufacturing. glucosidase deficiency).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

SEPTEMBER 9, 2020

Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community,” said Ugur Sahin, M.D., During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech Procedures should be in place to avoid injury from fainting. BioNTech COVID-19 Vaccine. The Pfizer?BioNTech

Government 52

Government Vaccine Clinical Trials Licensing 52